In a large series of cancers, PD-L1-positive tumors were more frequent in MET-altered NSCLC patients (84%) compared with the wild-type group (59%) and especially high PD-L1 expression (50%) was found in the MET-altered NSCLC group compared to the wild-type group (60% versus 30%) [30]. The gene discussed is CD274; the disease is cancer.